C07K 14/5412
Il-6
Official title: {il-6}
C07K14/5412 (Il-6) appears on 233 US grants and 257 published applications in this corpus.
Search patents in C07K- Granted patents
- 233
- Published applications
- 257
- Assignees
- 169
- Inventors
- 522
- Latest grant
- 18 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1991 | 1 | 0 |
| 1992 | 0 | 0 |
| 1993 | 4 | 0 |
| 1994 | 6 | 0 |
| 1995 | 8 | 0 |
| 1996 | 9 | 0 |
| 1997 | 18 | 0 |
| 1998 | 9 | 0 |
| 1999 | 9 | 0 |
| 2000 | 5 | 0 |
| 2001 | 6 | 1 |
| 2002 | 4 | 4 |
| 2003 | 4 | 9 |
| 2004 | 1 | 9 |
| 2005 | 4 | 12 |
| 2006 | 3 | 4 |
| 2007 | 6 | 7 |
| 2008 | 7 | 5 |
| 2009 | 5 | 10 |
| 2010 | 6 | 7 |
| 2011 | 10 | 9 |
| 2012 | 5 | 12 |
| 2013 | 9 | 9 |
| 2014 | 5 | 11 |
| 2015 | 8 | 11 |
| 2016 | 5 | 9 |
| 2017 | 8 | 9 |
| 2018 | 11 | 12 |
| 2019 | 7 | 12 |
| 2020 | 6 | 15 |
| 2021 | 15 | 11 |
| 2022 | 6 | 20 |
| 2023 | 6 | 14 |
| 2024 | 7 | 14 |
| 2025 | 6 | 14 |
| 2026 | 4 | 7 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Enhanced chimeric antigen receptor cells in hypoxic tumor microenvironment18 Aug 2026US 12,709,737 B2Innovative Cellular Therapeutics Holdings, Ltd.
- Bicyclic peptide ligands specific for CD13719 May 2026US 12,630,588 B2BicycleTx Limited
- Genetically modified immune cell, preparation method therefor, and application5 May 2026US 12,617,828 B2Shenzhen In Vivo Biomedicine Technology Limited Company
- TGF-β polypeptides20 Jan 2026US 12,528,850 B2Cue Biopharma, Inc.
- Method of assessing regulation of an immune response to an administered agent by measuring activation of nodose ganglion neurons30 Sep 2025US 12,427,206 B2The Trustees of Columbia University in the City of New York
- Methods for the production of dendritic cells by modulating retinoid signaling6 Aug 2026US 2026/0226411 A1FUJIFILM Holdings America Corporation
- Attenuation of cytokine release syndrome in immunotherapy4 Jun 2026US 2026/0152748 A1Microcrispr Pvt Ltd.
- Modified glucokinase nucleic acids for treating diabetes21 May 2026US 2026/0139024 A1Kriya Therapeutics, Inc.
- Regulation of immune responses through selective neural activation12 Feb 2026US 2026/0041796 A1The Trustees of Columbia University in the City of New York
- Methods for controlling osteocalcin release5 Feb 2026US 2026/0034225 A1The Trustees of Columbia University in the City of New York
Most cited
By later US patents
- Interleukin-1α antibodies1,029US 8,034,337 B2Xbiotech, Inc. · 2011
- Method for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells210US 5,437,994 AThe Regents of the University of Michigan · 1995
- Derivatives of growth hormone and related proteins160US 6,608,183 B1Bolder Biotechnology, Inc. · 2003
- Methods and compositions for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells159US 6,326,198 B1The Regents of the University of Michigan · 2001
- Methods, compositions and devices for maintaining and growing human stem and/or hematopoietics cells151US 5,763,266 AThe Regents of the University of Michigan · 1998